2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2...2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2060年达到中和的“双碳”目标。ESG与全球生态息息相关,也是推动经济高质量发展的重要工具,可以为中国实现“双碳”做出贡献。目前患肿瘤等疾病的人数不断攀升,肿瘤药物的创新研发具有重大意义,但同时制药又是重污染来源,亟需完善ESG治理。百济神州在生物创新药行业有一定的代表意义,本文以百济神州为例,研究其ESG信息披露的实践与可改进部分,从而给生物创新药行业带来借鉴意义。On April 12, 2024, the three major stock exchanges in Shanghai, Shenzhen and North China officially issued the Guidelines for Sustainability Reporting of Listed Companies (hereinafter referred to as the “Guidelines”), which will be implemented from May 1, 2024. In this context, President Xi Jinping has proposed to strive to peak carbon dioxide emissions by 2030 and achieve neutrality by 2060. ESG is closely related to the global ecology and is also an important tool to promote high-quality economic development, which can contribute to China’s “dual carbon” efforts. At present, the number of people suffering from tumors and other diseases is rising, and the innovative research and development of oncology drugs is of great significance, but at the same time, pharmaceuticals are a source of heavy pollution, and ESG governance needs to be improved urgently. BeiGene has a certain representative significance in the bio-innovative drug industry, and this article takes BeiGene as an example to study the practice and improvement of its ESG information disclosure, so as to bring reference significance to the bio-innovative drug industry.展开更多
Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treat...Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin. Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes. New therapies are classified as: (1) Anti-TNFα antibodies; (2) Recombinant cytokines; (3) Selective adhesion blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation. All treatments have the potential to provide more effective and safe treatment for IBD.展开更多
Aim: EPO (erythropoietin) is a hormone that stimulates the erythropoiesis and is mainly produced by the kidneys. In the early 1990s among the emerging biotech drugs, the recombinant human EPO (rhEPO) was the best...Aim: EPO (erythropoietin) is a hormone that stimulates the erythropoiesis and is mainly produced by the kidneys. In the early 1990s among the emerging biotech drugs, the recombinant human EPO (rhEPO) was the best-selling product worldwide, reaching nearly three billion dollars annually. The CIM (center of molecular immunology) produced and sold the rhEPO as commercial strategy to recover the investment made in its new facilities. This work summarizes the inventions that protect the innovative products developed by three Cuban institutions, starting from rhEPO, and the industrial property strategy followed by them. Methods: The information was obtained from the United States Patent, Trademark Office (USPTO) database, Patentscope, Espacenet, patent databases of Center for Pharmaceutical Research and Drug Development (CIDEM) and Cuban Industrial Property Office. Conclusions: The manufacturing process of CIM's EPO has its own patent family. From a manufacturing by product an innovative formulation protected by patent was obtained. There is a patent family around the nasal formulation and it continues enlarging. From a biosimilar pharmaceutical innovative products impacting on human health have been obtained.展开更多
Chemomics is an interdisciplinary study using approaches from chemoinformatics,bioinformatics,synthetic chemistry,and other related disciplines.Biological systems make natural products from endogenous small molecules ...Chemomics is an interdisciplinary study using approaches from chemoinformatics,bioinformatics,synthetic chemistry,and other related disciplines.Biological systems make natural products from endogenous small molecules (natural product building blocks) through a sequence of enzyme catalytic reactions.For each reaction,the natural product building blocks may contribute a group of atoms to the target natural product.We describe this group of atoms as a chemoyl.A chemome is the complete set of chemoyls in an organism.Chemomics studies chemomes and the principles of natural product syntheses and evolutions.Driven by survival and reproductive demands,biological systems have developed effective protocols to synthesize natural products in order to respond to environmental changes;this results in biological and chemical diversity.In recent years,it has been realized that one of the bottlenecks in drug discovery is the lack of chemical resources for drug screening.Chemomics may solve this problem by revealing the rules governing the creation of chemical diversity in biological systems,and by developing biomimetic synthesis approaches to make quasi natural product libraries for drug screening.This treatise introduces chemomics and outlines its contents and potential applications in the fields of drug innovation.展开更多
文摘2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2060年达到中和的“双碳”目标。ESG与全球生态息息相关,也是推动经济高质量发展的重要工具,可以为中国实现“双碳”做出贡献。目前患肿瘤等疾病的人数不断攀升,肿瘤药物的创新研发具有重大意义,但同时制药又是重污染来源,亟需完善ESG治理。百济神州在生物创新药行业有一定的代表意义,本文以百济神州为例,研究其ESG信息披露的实践与可改进部分,从而给生物创新药行业带来借鉴意义。On April 12, 2024, the three major stock exchanges in Shanghai, Shenzhen and North China officially issued the Guidelines for Sustainability Reporting of Listed Companies (hereinafter referred to as the “Guidelines”), which will be implemented from May 1, 2024. In this context, President Xi Jinping has proposed to strive to peak carbon dioxide emissions by 2030 and achieve neutrality by 2060. ESG is closely related to the global ecology and is also an important tool to promote high-quality economic development, which can contribute to China’s “dual carbon” efforts. At present, the number of people suffering from tumors and other diseases is rising, and the innovative research and development of oncology drugs is of great significance, but at the same time, pharmaceuticals are a source of heavy pollution, and ESG governance needs to be improved urgently. BeiGene has a certain representative significance in the bio-innovative drug industry, and this article takes BeiGene as an example to study the practice and improvement of its ESG information disclosure, so as to bring reference significance to the bio-innovative drug industry.
文摘Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin. Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes. New therapies are classified as: (1) Anti-TNFα antibodies; (2) Recombinant cytokines; (3) Selective adhesion blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation. All treatments have the potential to provide more effective and safe treatment for IBD.
文摘Aim: EPO (erythropoietin) is a hormone that stimulates the erythropoiesis and is mainly produced by the kidneys. In the early 1990s among the emerging biotech drugs, the recombinant human EPO (rhEPO) was the best-selling product worldwide, reaching nearly three billion dollars annually. The CIM (center of molecular immunology) produced and sold the rhEPO as commercial strategy to recover the investment made in its new facilities. This work summarizes the inventions that protect the innovative products developed by three Cuban institutions, starting from rhEPO, and the industrial property strategy followed by them. Methods: The information was obtained from the United States Patent, Trademark Office (USPTO) database, Patentscope, Espacenet, patent databases of Center for Pharmaceutical Research and Drug Development (CIDEM) and Cuban Industrial Property Office. Conclusions: The manufacturing process of CIM's EPO has its own patent family. From a manufacturing by product an innovative formulation protected by patent was obtained. There is a patent family around the nasal formulation and it continues enlarging. From a biosimilar pharmaceutical innovative products impacting on human health have been obtained.
基金supported by the National Science and Technology Major Project of China (2010ZX09102-305)the National High-tech R&D Program of China (863 Program,2012AA020307)+1 种基金the Introduction of Innovative R&D Team Program of Guangdong Province (2009010058)the National Natural Science Foundation of China (81173470)
文摘Chemomics is an interdisciplinary study using approaches from chemoinformatics,bioinformatics,synthetic chemistry,and other related disciplines.Biological systems make natural products from endogenous small molecules (natural product building blocks) through a sequence of enzyme catalytic reactions.For each reaction,the natural product building blocks may contribute a group of atoms to the target natural product.We describe this group of atoms as a chemoyl.A chemome is the complete set of chemoyls in an organism.Chemomics studies chemomes and the principles of natural product syntheses and evolutions.Driven by survival and reproductive demands,biological systems have developed effective protocols to synthesize natural products in order to respond to environmental changes;this results in biological and chemical diversity.In recent years,it has been realized that one of the bottlenecks in drug discovery is the lack of chemical resources for drug screening.Chemomics may solve this problem by revealing the rules governing the creation of chemical diversity in biological systems,and by developing biomimetic synthesis approaches to make quasi natural product libraries for drug screening.This treatise introduces chemomics and outlines its contents and potential applications in the fields of drug innovation.